» Articles » PMID: 27510381

Detection of MYCN Amplification in Serum DNA Using Conventional Polymerase Chain Reaction

Overview
Specialty General Medicine
Date 2016 Aug 12
PMID 27510381
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Neuroblastoma (NB) is the most common extra-cranial solid tumor of childhood and is characterized by a wide range of clinical behaviors. Amplification of MYCN is a well-known poor prognostic factor in NB patients. As the MYCN amplification status is usually tested using tumor specimens, lengthy and invasive procedures are unavoidable. To evaluate the possibility of detecting MYCN amplification without invasive procedure, we performed conventional polymerase chain reaction (PCR) analysis to identify MYCN amplification using the preserved serum DNA. PCR of serum DNA was done in 105 NB patients whose MYCN status had been confirmed by fluorescence in situ hybridization. MYCN amplification was evaluated as the ratio of signal intensities between MYCN and NAGK (M/N ratio). When regarding the tissue FISH results as a reference, 10 patients had MYCN-amplified (MNA) NB, and 95 had non-MNA NB. The M/N ratio of the MNA group (median 2.56, range 1.01-3.58) was significantly higher than that of the non-MNA group (median 0.97, range 0.67-5.18) (P < 0.001). In the receiver operating characteristic curve analysis, the area under the curve was 0.957 (95% confidence interval 0.898-1.000; P < 0.001), and it showed 90.9% sensitivity and 97.9% specificity with the selected cut-off value set as 1.6. The detection of MYCN amplification using conventional PCR analysis of serum samples seems to be a simple and promising method to evaluate the MYCN status of NB patients. Further study with a larger set of patients is needed to confirm the accuracy of this result.

Citing Articles

A comprehensive overview of liquid biopsy applications in pediatric solid tumors.

Janssen F, Lak N, Janda C, Kester L, Meister M, Merks J NPJ Precis Oncol. 2024; 8(1):172.

PMID: 39097671 PMC: 11297996. DOI: 10.1038/s41698-024-00657-z.


Advances in liquid biopsy in neuroblastoma.

Zhuo Z, Lin L, Miao L, Li M, He J Fundam Res. 2024; 2(6):903-917.

PMID: 38933377 PMC: 11197818. DOI: 10.1016/j.fmre.2022.08.005.


MYCN protein stability is a better prognostic indicator in neuroblastoma.

Yang Y, Zhao J, Zhang Y, Feng T, Yv B, Wang J BMC Pediatr. 2022; 22(1):404.

PMID: 35820898 PMC: 9277955. DOI: 10.1186/s12887-022-03449-1.


Opportunities and challenges of circulating biomarkers in neuroblastoma.

Trigg R, Shaw J, Turner S Open Biol. 2019; 9(5):190056.

PMID: 31088252 PMC: 6544987. DOI: 10.1098/rsob.190056.

References
1.
Brodeur G, Seeger R, Schwab M, Varmus H, Bishop J . Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984; 224(4653):1121-4. DOI: 10.1126/science.6719137. View

2.
Canete A, Gerrard M, Rubie H, Castel V, Di Cataldo A, Munzer C . Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience. J Clin Oncol. 2009; 27(7):1014-9. DOI: 10.1200/JCO.2007.14.5839. View

3.
Tonini G, Boni L, Rogers D, Iolascon A, Basso G, Cordero di Montezemolo L . MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children. J Clin Oncol. 1997; 15(1):85-93. DOI: 10.1200/JCO.1997.15.1.85. View

4.
Shimada H, Ambros I, Dehner L, Hata J, JOSHI V, Roald B . The International Neuroblastoma Pathology Classification (the Shimada system). Cancer. 1999; 86(2):364-72. View

5.
Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View